Yacoub Faroun, MD
Hematology & Oncology · Easton, PANPI 1619961133
Payments from drug & device makers
Across 363 payments — averaging $2659.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$268K
- Pfizer$198K
- AstraZeneca$174K
- E.r. Squibb & Sons, L.L.C.$149K
- Merck$109K
- Gilead$22K
- plus $45K from 21 others
Across 4 payments — averaging $825.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
What the payments were for
- Consulting fees$54,77382%
- Speaking & faculty fees$6,59010%
- Travel & lodging$2,1343%
- Food & beverage$1,2312%
- Education$1,7163%
- Other$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 104 | $268,382 |
| Pfizer | 109 | $198,169 |
| AstraZeneca(2 entities) | 32 | $174,126 |
| E.r. Squibb & Sons, L.L.C. | 20 | $149,209 |
| Merck | 16 | $109,379 |
| Gilead | 13 | $21,740 |
| Johnson & Johnson | 8 | $6,566 |
| Amgen | 7 | $5,997 |
| Bristol Myers Squibb | 8 | $5,212 |
| Sanofi | 5 | $4,963 |
| Incyte Corporation | 2 | $3,883 |
| Exelixis Inc. | 3 | $3,040 |
| Bayer | 4 | $2,638 |
| Immunomedics, Inc. | 1 | $2,600 |
| Karyopharm Therapeutics Inc. | 2 | $2,259 |
| Seagen Inc. | 9 | $1,610 |
| Jazz Pharmaceuticals Inc. | 1 | $1,260 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,050 |
| Astellas Pharma US Inc | 7 | $938 |
| Beigene USA, Inc. | 2 | $702 |
| Daiichi Sankyo Inc. | 1 | $650 |
| EMD Serono, Inc. | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Novartis | 2 | $125 |
| Lilly USA, LLC | 1 | $60 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $35 |
| Array Biopharma Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$965,563 in reported general payments places this provider in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 75 | $1,298,838 |
| Lenalidomide | 73 | $1,086,632 |
| XtandiEnzalutamide | 85 | $927,185 |
| PomalystPomalidomide | 38 | $862,380 |
| ImbruvicaIbrutinib | 74 | $839,129 |
| BrukinsaZanubrutinib | 74 | $766,817 |
| CalquenceAcalabrutinib Maleate | 67 | $719,204 |
| ErleadaApalutamide | 49 | $625,884 |
| Abiraterone Acetate | 264 | $481,277 |
| XospataGilteritinib Fumarate | 17 | $388,185 |
| CabometyxCabozantinib S-Malate | 12 | $266,754 |
| LynparzaOlaparib | 20 | $253,662 |
| KisqaliRibociclib Succinate | 18 | $246,647 |
| IbrancePalbociclib | 18 | $238,577 |
| JakafiRuxolitinib Phosphate | 21 | $238,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Xospata | $938 | $1,315,370102 claims |
| Bristol Myers SquibbRevlimid | $5,212 | $1,298,83875 claims |
| AstraZenecaCalquence, Lynparza | $174,126 | $972,86687 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $149,209 | $937,87751 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $35 | $839,12974 claims |
| Beigene USA, Inc.Brukinsa | $702 | $766,81774 claims |
| Johnson & JohnsonErleada, Xarelto | $6,566 | $672,70187 claims |
| NovartisKisqali, Promacta | $125 | $448,49036 claims |
| PfizerIbrance, Eliquis | $198,169 | $350,840170 claims |
| Exelixis Inc.Cabometyx | $3,040 | $266,75412 claims |
| Incyte CorporationJakafi | $3,883 | $238,14821 claims |
| Lilly USA, LLCVerzenio | $60 | $171,78912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Easton
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.